Comparative safety and efficacy of statins for primary prevention in human immunodeficiency virus-positive patients: A systematic review and meta-analysis

European Heart Journal

Volumn 37, Issue 48, 2016, Pages 3600-3609

  Gili, Sebastiano ^a,b   Marra, Walter Grosso ^a   D'Ascenzo, Fabrizio ^a,b   Lonni, Enrica ^a   Calcagno, Andrea ^c   Cannillo, Margherita ^a   Ballocca, Flavia ^a   Cerrato, Enrico ^a,b   Pianelli, Martina ^a   Barbero, Umberto ^a   Mancone, Massimo ^d   DiNicolantonio, James J ^e   Lavie, Carl J ^f   Omedè, Pierluigi ^a,b   Montefusco, Antonio ^a,b   Bonora, Stefano ^c   Gasparini, Mauro ^g   Biondi Zoccai, Giuseppe ^b,h   Moretti, Claudio ^a,b   Gaita, Fiorenzo ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b Cardiogrouporg Collaborative Group   (Italy)

^c AMEDEO DI SAVOIA HOSPITAL   (Italy)

^d POLICLINICO UMBERTO I   (Italy)

^e ST LUKE S HOSPITAL   (United States)

^f JOHN OCHSNER HEART AND VASCULAR INSTITUTE   (United States)

^g POLITECNICO DI TORINO   (Italy)

^h SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Antiretroviral therapy; Cardiovascular risk; Dyslipidaemia; HIV positive patients; Statin therapy

Indexed keywords

ATORVASTATIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PRAVASTATIN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PYRROLE DERIVATIVE;

ANTIRETROVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERNAL VALIDITY; META ANALYSIS; PRIMARY PREVENTION; PRIORITY JOURNAL; SYSTEMATIC REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; ADULT; COMPARATIVE STUDY; FEMALE; MALE;

ADULT; ANTICHOLESTEREMIC AGENTS; ATORVASTATIN CALCIUM; CHOLESTEROL, LDL; FEMALE; HIV INFECTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PRIMARY PREVENTION; PYRROLES; ROSUVASTATIN CALCIUM; SIMVASTATIN;

EID: 85013498696     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehv734     Document Type: Article

References (45)

1. D'Ascenzo F, Cerrato E, Appleton D, Moretti C, Calcagno A, Abouzaki N, Vetrovec G, Lhermusier T, Carrie D, Das Neves B, Escaned J, Cassese S, Kastrati A, Chinaglia A, Belli R, Capodanno D, Tamburino C, Santilli F, Parodi G, Vachiat A, Manga P, Vignali L, Mancone M, Sardella G, Fedele F, DiNicolantonio JJ, Omedè P, Bonora S, Gaita F, Abbate A, Zoccai GB; Percutaneous Coronary Intervention and Surgical Revascularization in HIV Database (PHD) Study Investigators. Prognostic indicators for recurrent thrombotic events in HIV-infected patients with acute coronary syndromes: use of registry data from 12 sites in Europe, South Africa and the United States. Thromb Res 2014;134: 558-564.
2. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015;385:117-171.
3. Cerrato E, D'Ascenzo F, Biondi-Zoccai G, Calcagno A, Frea S, Grosso Marra W, Castagno D, Omedè P, Quadri G, Sciuto F, Presutti D, Frati G, Bonora S, Moretti C, Gaita F. Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era. Eur Heart J 2013;34:1432-1436.
4. Riddler SA, Smit E, Cole SR, Li R, Chmiel JS, Dobs A, Palella F, Visscher B, Evans R, Kingsley LA. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003;289:2978-2982.
5. Penzak SR, Chuck SK, Stajich GV. Safety and efficacy of HMG-CoA reductase inhibitors for treatment of hyperlipidemia in patients with HIV infection. Pharmacotherapy 2000;20:1066-1071.
6. Ganesan A, Crum-Cianflone N, Higgins J, Qin J, Rehm C, Metcalf J, Brandt C, Vita J, Decker CF, Sklar P, Bavaro M, Tasker S, Follmann D, Maldarelli F. High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial. J Infect Dis 2011;203:756-764.
7. D'Ascenzo F, Agostoni P, Abbate A, Castagno D, Lipinski MJ, VetrovecGW, Frati G, Presutti DG, Quadri G, Moretti C, Gaita F, Zoccai GB. Atherosclerotic coronary plaque regression and the risk of adverse cardiovascular events: a meta-regression of randomized clinical trials. Atherosclerosis 2013;226:178-185.
8. Feinstein MJ, Achenbach CJ, Stone NJ, Lloyd-Jones DM. A systematic review of the usefulness of statin therapy in HIV-infected patients. Am J Cardiol 2015;115: 1760-1766.
9. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700.
10. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 1999;354:1896-1900.
11. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008-2012.
12. Wilczynski NL, Haynes RB; for the Hedges Team. Developing optimal search strategies for detecting clinically sound prognostic studies in MEDLINE: an analytic survey. BMC Med 2004;2:23.
13. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration; 2009. www. cochrane-handbook.org.
14. Benesic A, Zilly M, Kluge F,Weissbrich B, Winzer R, Klinker H, Langmann P. Lipid lowering therapy with fluvastatin and pravastatin in patients with HIV infection and antiretroviral therapy: comparison of efficacy and interaction with indinavir. Infection 2004;32:229-233.
15. Calza L, Manfredi R, Colangeli V, Pocaterra D, Pavoni M, Chiodo F. Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolaemia in HIV-infected patients receiving protease inhibitors. Curr HIV Res 2008;6:572-578.
16. Aberg JA, Zackin RA, Brobst SW, Evans SR, Alston BL, Henry WK, Glesby MJ, Torriani FJ, Yang Y, Owens SI, Fichtenbaum CJ; ACTG 5087 Study Team. A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087. AIDS Res Hum Retroviruses 2005;21:757-767.
17. Aslangul E, Assoumou L, Bittar R, Valantin MA, Kalmykova O, Peytavin G, Fiévet MH, Boccara F, Bonnefont-Rousselot D, Melchior JC, Giral P, Costagliola D. Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial. AIDS 2010;24:77-83.
18. Bonnet F, Aurillac-Lavignolle V, Breilh D, Thiébaut R, Peuchant E, Bernard N, Lacoste D, Dabis F, Beylot J, Chêne G, Morlat P; GECSA. Pravastatin in HIV-infected patients treated with protease inhibitors: a placebo-controlled randomized study. HIV Clin Trials 2007;8:53-60.
19. Calmy A, Bloch M, Wand H, Delhumeau C, Finlayson R, Rafferty M, Norris R, Hirschel B, Cooper DA, Carr A; URISTAT Study Group. No significant effect of uridine or pravastatin treatment for HIV lipoatrophy in men who have ceased thymidine analogue nucleoside reverse transcriptase inhibitor therapy: a randomized trial. HIV Med 2010;11:493-501.
20. Calza L, Trapani F, Bartoletti M, Manfredi R, Colangeli V, Borderi M, Grossi G, Motta R, Viale P. Statin therapy decreases serum levels of high-sensitivity C-reactive protein and tumor necrosis factor - a in HIV-infected patients treated with Ritonavir-boosted protease inhibitors. HIV Clin Trials 2012;13:153-161.
21. de Luis DA, Bachiller P, Aller R, Eiros Bouza J, Izaola O. Pravastatin in hyperlipidemia secondary to HIV protease inhibitors without response to fenofibrate: a brief preliminary report. Nutrition 2003;19:903-904.
22. Macallan DC, Baldwin C, Mandalia S, Pandol-Kaljevic V, Higgins N, Grundy A, Moyle GJ. Treatment of altered body composition in HIV-associated lipodystrophy: comparison of rosiglitazone, pravastatin, and recombinant human growth hormone. HIV Clin Trials 2008;9:254-268.
23. Mallon PW, Miller J, Kovacic JC, Kent-Hughes J, Norris R, Samaras K, Feneley MP, Cooper DA, Carr A. Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men - a randomized, placebo-controlled study. AIDS 2006;20:1003-1010.
24. Stein JH, Merwood MA, Bellehumeur JL, Aeschlimann SE, Korcarz CE, Underbakke GL, Mays ME, Sosman JM. Effects of pravastatin on lipoproteins and endothelial function in patients receiving human immunodeficiency virus protease inhibitors. Am Heart J 2004;147:E18.
25. Calza L, Colangeli V, Manfredi R, Legnani G, Tampellini L, Pocaterra D, Chiodo F. Rosuvastatin for the treatment of hyperlipidaemia in HIV-infected patients receiving protease inhibitors: a pilot study. AIDS 2005;19:1103-1105.
26. Calza L, Manfredi R, Colangeli V, Trapani FF, Salvadori C, Magistrelli E, Danese I, Verucchi G, Serra C, Viale P. Two-year treatment with rosuvastatin reduces carotid intima-media thickness in HIV type 1-infected patients receiving highly active antiretroviral therapy with asymptomatic atherosclerosis and moderate cardiovascular risk. AIDS Res Hum Retroviruses 2013;29:547-556.
27. Calza L, Vanino E, Salvadori C, Manfredi R, Colangeli V, Cascavilla A, Di Bari MA, Motta R, Viale P. Tenofovir/emtricitabine/efavirenz plus rosuvastatin decrease serum levels of inflammatory markers more than antiretroviral drugs alone in antiretroviral therapy-naive HIV-infected patients. HIV Clin Trials 2014;15:1-13.
28. Eckard AR, Jiang Y, Debanne SM, Funderburg NT, McComsey GA. Effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects receiving antiretroviral therapy. J Infect Dis 2014;209:1156-1164.
29. Lo J, Lu MT, Ihenachor EJ, Wei J, Looby SE, Fitch KV, Oh J, Zimmerman CO, Hwang J, Abbara S, Plutzky J, Robbins G, Tawakol A, Hoffmann U, Grinspoon SK. Effects of statin therapy on coronary artery plaque volume and highrisk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial. Lancet HIV 2015;2:e52-e63.
30. Nakanjako D, Ssinabulya I, Nabatanzi R, Bayigga L, Kiragga A, Joloba M, Kaleebu P, Kambugu AD, Kamya MR, Sekaly R, Elliott A, Mayanja-Kizza H. Atorvastatin reduces T-cell activation and exhaustion among HIV-infected cART-treated suboptimal immune responders in Uganda: a randomised crossover placebo-controlled trial. Trop Med Int Health 2015;20:380-390.
31. Rahman AP, Eaton SA, Nguyen ST, Bain AM, Payne KD, Bedimo R, Busti AJ. Safety and efficacy of simvastatin for the treatment of dyslipidemia in human immunodeficiency virus-infected patients receiving efavirenz-based highly active antiretroviral therapy. Pharmacotherapy 2008;28:913-919.
32. Friis-Møller N, Thiébaut R, Reiss P,Weber R, Monforte AD, De Wit S, El-SadrW, Fontas E,Worm S, Kirk O, Phillips A, Sabin CA, Lundgren JD, Law MG; DAD study group. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil 2010;17:491-501.
33. Martinez E, Conget I, Lozano L, Casamitjana R, Gatell JM. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999;13:805-810.
34. Zanni MV, Fitch KV, Feldpausch M, Han A, Lee H, Lu MT, Abbara S, Ribaudo H, Douglas PS, Hoffmann U, Lo J, Grinspoon SK. 2013 American College of Cardiology/ American Heart Association and 2004 Adult Treatment Panel III cholesterol guidelines applied to HIV-infected patients with/without subclinical high-risk coronary plaque. AIDS 2014;28:2061-2070.
35. Hardoon SL, Morris RW, Whincup PH, Shipley MJ, Britton AR, Masset G, Stringhini S, Sabia S, Kivimaki M, Singh-Manoux A, Brunner EJ. Rising adiposity curbing decline in the incidence of myocardial infarction: 20-year follow-up of British men and women in the Whitehall II cohort. Eur Heart J 2012;33:478-485.
36. Masiá M, Bernal E, Robledano C, Padilla S, López N, Martínez E, Gutiérrez F. Longterm effects of an intensive intervention in HIV-infected patients with moderate-high atherosclerotic cardiovascular risk. J Antimicrob Chemother 2014;69:3051-3056.
37. Sponseller CA, Morgan RE, Kryzhanovski VA, Campbell SE, Davidson MH. Comparison of the lipid-lowering effects of pitavastatin 4 mg versus pravastatin 40 mg in adults with primary hyperlipidemia or mixed (combined) dyslipidemia: a Phase IV, prospective, US, multicenter, randomized, double blind, superiority trial. Clin Ther 2014;36:1211-1222.
38. Adams SP, Sekhon SS, Wright JM. Lipid-lowering efficacy of rosuvastatin. Cochrane Database Syst Rev 2014;11:CD010254.
39. Adams SP, Tsang M, Wright JM. Lipid-lowering efficacy of atorvastatin. Cochrane Database Syst Rev 2015;3:CD008226.
40. Townsend ML, Hollowell SB, Bhalodia J, Wilson KH, Kaye KS, Johnson MD. A comparison of the effectiveness of lipid-lowering therapy between HIV-and non-HIV-infected subjects with hyperlipidaemia. Int J STD AIDS 2007;18:851-855.
41. Silverberg MJ, Leyden W, Hurley L, Go AS, Quesenberry CP Jr, Klein D, Horberg MA. Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection. Ann Intern Med 2009;150:301-313.
42. Kashani A, Phillips CO, Foody JM, Wang Y, Mangalmurti S, Ko DT, Krumholz HM. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 2006;114:2788-2797.
43. Di Giambenedetto S, Fabbiani M, Colafigli M, Ciccarelli N, Farina S, Sidella L, D'Avino A, Mondi A, Cingolani A, Tamburrini E, Murri R, Navarra P, Cauda R, De Luca A. Safety and feasibility of treatment simplification to atazanavir/ ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos( t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study). J Antimicrob Chemother 2013;68:1364-1372.
44. Aquilante CL, Kiser JJ, Anderson PL, Christians U, Kosmiski LA, Daily EB, Hoffman KL, Hopley CW, Predhomme JA, Schniedewind B, Sidhom MS. Influence of SLCO1B1 polymorphisms on the drug-drug interaction between darunavir/ritonavir and pravastatin. J Clin Pharmacol 2012;52:1725-1738.
45. D'Ascenzo F, Biondi-Zoccai G. Network meta-analyses: the "white whale" for cardiovascular specialists. J Cardiothorac Vasc Anesth 2014;28:169-173.